COMPARING OF FAECAL CALPROTECTIN LEVELS IN PATIENTS WITH OSTEOARTHRITIS TAKING NSAID TREATMENT AND PATIENTS WITHOUT NSAIDS THERAPY
| Autor: | Artem Panin, A. A. Kuzminets, Olena Gubska |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
lcsh:Medicine Osteoarthritis Neutrophilic inflammation nsaids Systemic inflammation calprotectin digestive system Gastroenterology 03 medical and health sciences 0302 clinical medicine Degenerative disease colopathy Internal medicine medicine Enteropathy In patient skin and connective tissue diseases business.industry lcsh:R medicine.disease Faecal calprotectin digestive system diseases osteoarthritis enteropathy 030220 oncology & carcinogenesis 030211 gastroenterology & hepatology medicine.symptom Calprotectin business |
| Zdroj: | EUREKA: Health Sciences, Vol 0, Iss 2, Pp 17-24 (2020) |
| ISSN: | 2504-5679 2504-5660 |
| Popis: | Faecal calprotectin (FC) level can be increased in several conditions, which are characterised by neutrophilic inflammation. Some medications, particularly NSAIDs, can elevate its level as well. NSAIDs are taken by patients in many chronic conditions, including osteoarthritis (OA). On the other hand, there is growing evidence that osteoarthritis is not only a degenerative disease, but it has a significant inflammatory component. The role of systemic inflammation is well-known in inflammatory joint diseases, but there is some evidence that it can play an essential role in the OA as well. It can suggest that in the OA, the inflammatory changes could be found in the different organs and systems. The aim of this studywas to investigate the FC level in patients with osteoarthritis depending on the NSAIDs intake and to compare it to the FC levels in healthy adults. Materials and methods. In this small observational study, we evaluated the FC levels in patients suffering from OA (36 persons), divided them into two groups depending on their NSAIDs intake, and compared it to FC levels in healthy participants (12 persons). We compared the FC levels depending on the selectivity of the NSAIDs taken by our participants, as well. Results.The median calprotectin level in our patients was 72.57 (IQR 20.55-221.57) mg/kg, 95 %CI 26,18-109.01. OA patients had higher levels than the healthy group (p0.05). Conclusions.Patients who suffer from OA have higher FC levels than healthy individuals, and patients with OA who take NSAIDs regularly have higher FC levels than those who do not. The intake of non-selective NSAIDs is associated with higher FC levels, than the intake of high-selective NSAIDs. FC levels of those who take high-selective NSAIDs do not differ statistically from those who do not intake NSAIDs. Further research is needed in this area. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|